Biotech and drug stocks
7.47k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| Biotech and drug stocks | +1.24% | - | - | - |
| ^GSPC | +0.80% | +4.21% | +23.24% | +5574.74% |
31 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 820.34 | +5.28 | +0.65% | 4:04 pm GMT-4 | 4.33M | 2.71M | 779.66B |
| NVO | Novo Nordisk A/S | 135.28 | +2.48 | +1.87% | 4:00 pm GMT-4 | 3.20M | 4.36M | 602.60B |
| JNJ | Johnson & Johnson | 146.67 | +1.39 | +0.96% | 4:00 pm GMT-4 | 12.59M | 7.70M | 352.99B |
| MRK | Merck & Co., Inc. | 125.54 | +1.01 | +0.81% | 4:00 pm GMT-4 | 17.89M | 8.57M | 317.97B |
| ABBV | AbbVie Inc. | 161.24 | +4.93 | +3.15% | 4:05 pm GMT-4 | 15.00M | 5.78M | 284.73B |
| AZN | AstraZeneca PLC | 78.02 | +1.25 | +1.63% | 4:00 pm GMT-4 | 4.21M | 5.23M | 241.90B |
| NVS | Novartis AG | 103.13 | +2.43 | +2.41% | 4:00 pm GMT-4 | 1.97M | 1.49M | 210.43B |
| RHHBY | Roche Holding AG | 32.01 | +0.44 | +1.39% | 4:00 pm GMT-4 | 1.96M | 2.97M | 206.41B |
| AMGN | Amgen Inc. | 305.85 | +4.85 | +1.61% | 4:00 pm GMT-4 | 4.23M | 2.67M | 164.07B |
| PFE | Pfizer Inc. | 28.66 | +0.46 | +1.63% | 4:00 pm GMT-4 | 75.01M | 42.12M | 162.40B |
| SNY | Sanofi | 49.03 | +1.20 | +2.51% | 4:00 pm GMT-4 | 1.78M | 1.98M | 122.55B |
| VRTX | Vertex Pharmaceuticals Incorporated | 455.34 | +12.29 | +2.77% | 4:00 pm GMT-4 | 2.31M | 1.06M | 117.50B |
| REGN | Regeneron Pharmaceuticals, Inc. | 980.16 | +10.25 | +1.06% | 4:00 pm GMT-4 | 808.76k | 440.60k | 108.00B |
| GSK | GSK plc | 44.77 | +0.75 | +1.70% | 4:00 pm GMT-4 | 3.37M | 3.12M | 91.29B |
| BMY | Bristol-Myers Squibb Company | 41.09 | +0.84 | +2.09% | 4:00 pm GMT-4 | 24.78M | 16.18M | 83.29B |
| GILD | Gilead Sciences, Inc. | 64.27 | +0.19 | +0.30% | 4:00 pm GMT-4 | 14.10M | 7.04M | 80.07B |
| ZTS | Zoetis Inc. | 169.56 | +0.12 | +0.07% | 4:00 pm GMT-4 | 4.06M | 3.65M | 77.37B |
| MRNA | Moderna, Inc. | 142.55 | -8.94 | -5.90% | 4:00 pm GMT-4 | 7.15M | 4.06M | 54.63B |
| TAK | Takeda Pharmaceutical Company Limited | 13.35 | +0.32 | +2.46% | 4:00 pm GMT-4 | 1.85M | 1.57M | 41.89B |
| HLN | Haleon plc | 8.44 | +0.06 | +0.72% | 4:00 pm GMT-4 | 3.57M | 6.91M | 38.54B |
| BIIB | Biogen Inc. | 224.94 | +4.87 | +2.21% | 4:00 pm GMT-4 | 1.82M | 1.22M | 32.75B |
| BAYRY | Bayer Aktiengesellschaft | 7.72 | +0.07 | +0.92% | 3:59 pm GMT-4 | 2.12M | 2.12M | 30.34B |
| BNTX | BioNTech SE | 100.6 | +1.85 | +1.87% | 4:00 pm GMT-4 | 1.56M | 723.66k | 24.24B |
| ARGX | argenx SE | 371.02 | +8.86 | +2.45% | 4:00 pm GMT-4 | 330.66k | 271.66k | 22.05B |
| TEVA | Teva Pharmaceutical Industries Limited | 16.93 | +0.03 | +0.18% | 4:00 pm GMT-4 | 7.21M | 9.86M | 19.18B |
| ALNY | Alnylam Pharmaceuticals, Inc. | 148.43 | -1.60 | -1.07% | 4:00 pm GMT-4 | 1.22M | 559.45k | 18.78B |
| GMAB | Genmab A/S | 28.2 | +0.21 | +0.75% | 4:00 pm GMT-4 | 461.84k | 482.25k | 18.18B |
| ALPMY | Astellas Pharma Inc. | 9.81 | +0.12 | +1.24% | 3:59 pm GMT-4 | 508.63k | 345.27k | 17.69B |
| RPRX | Royalty Pharma plc | 27.41 | +1.02 | +3.87% | 4:00 pm GMT-4 | 6.68M | 2.69M | 16.38B |
| BMRN | BioMarin Pharmaceutical Inc. | 75.07 | +0.59 | +0.79% | 4:00 pm GMT-4 | 2.01M | 1.70M | 14.25B |
Clinical Trials ArenaASCO 24: Data shows survival benefit with J&J’s subcutaneous Rybrevant
J&J's Rybrevant is expected to generate $4bn in sales by 2030, as per GlobalData estimates.
Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia
Business WireTeva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients’ quality of life. These interim findings from the IMPACT-TD study were presented at the 2024 Psych Congress Elevate Annual Meeting, taking place from May 30 –
